(%)
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
- Ownership
-
Voyager Therapeutics, Inc. Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Wednesday, April 23rd, 2025 | 2023 | Nathan Jorgensen, Ph D. Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Wednesday, April 23rd, 2025 | 2024 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 652,080 | 0 | 988,000 | 351,471 | 13,050 | 3,377,401 |
| Wednesday, April 23rd, 2025 | 2023 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 624,000 | 0 | 891,600 | 377,520 | 13,050 | 3,172,433 |
| Wednesday, April 23rd, 2025 | 2024 | Toby Ferguson, M.D., Ph.D. Chief Medical Officer | 367,792 | 0 | 1,106,700 | 148,159 | 13,050 | 2,969,200 |
| Wednesday, April 23rd, 2025 | 2023 | Toby Ferguson, M.D., Ph.D. Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Wednesday, April 23rd, 2025 | 2024 | Nathan Jorgensen, Ph D. Chief Financial Officer | 228,000 | 0 | 468,000 | 90,914 | 13,050 | 1,869,964 |
| Thursday, April 25th, 2024 | 2022 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 525,414 | 50,000 | 855,000 | 250,000 | 10,385 | 7,406,449 |
| Thursday, April 25th, 2024 | 2023 | Robin Swartz | 449,400 | 0 | 297,200 | 199,534 | 13,050 | 1,381,272 |
| Thursday, April 25th, 2024 | 2023 | Jacquelyn Fahey Sandell | 207,692 | 0 | 472,750 | 93,960 | 7,010 | 1,677,297 |
| Thursday, April 25th, 2024 | 2023 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 624,000 | 0 | 891,600 | 377,520 | 13,050 | 3,172,433 |
| Thursday, April 27th, 2023 | 2022 | Peter P. Pfreundschuh Chief Financial Officer | 122,500 | 0 | 740,000 | 50,229 | 0 | 1,791,949 |
| Thursday, April 27th, 2023 | 2021 | Peter P. Pfreundschuh Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 27th, 2023 | 2022 | Michael Higgins Former Interim President and Chief Executive Officer | 235,727 | 0 | 128,834 | 0 | 0 | 757,533 |
| Thursday, April 27th, 2023 | 2021 | Michael Higgins Former Interim President and Chief Executive Officer | 379,181 | 0 | 0 | 0 | 0 | 696,063 |
| Thursday, April 27th, 2023 | 2022 | Robert W. Hesslein Senior Vice President and General Counsel | 450,754 | 0 | 57,000 | 175,433 | 0 | 914,571 |
| Thursday, April 27th, 2023 | 2022 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 525,414 | 50,000 | 855,000 | 250,000 | 0 | 7,396,064 |
| Thursday, April 27th, 2023 | 2021 | Robert W. Hesslein Senior Vice President and General Counsel | 430,000 | 0 | 415,420 | 141,106 | 0 | 1,309,444 |
| Thursday, April 27th, 2023 | 2021 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 21st, 2022 | 2021 | Robert W. Hesslein Senior Vice President and General Counsel | 435,511 | 0 | 415,420 | 141,106 | 0 | 1,314,955 |
| Thursday, April 21st, 2022 | 2021 | Allison Dorval Former Chief Financial Officer | 393,185 | 0 | 415,420 | 0 | 0 | 1,131,523 |
| Thursday, April 21st, 2022 | 2021 | G. Andre Turenne Former President and Chief Executive Officer | 600,300 | 0 | 1,132,220 | 0 | 0 | 2,630,096 |
| Thursday, April 21st, 2022 | 2020 | G. Andre Turenne Former President and Chief Executive Officer | 580,000 | 0 | 1,053,000 | 293,480 | 0 | 3,274,275 |
| Thursday, April 21st, 2022 | 2020 | Robert W. Hesslein Senior Vice President and General Counsel | 420,784 | 0 | 356,400 | 157,037 | 2,829 | 1,393,160 |
| Thursday, April 21st, 2022 | 2020 | Allison Dorval Former Chief Financial Officer | 403,104 | 0 | 356,400 | 150,438 | 550 | 1,366,602 |
| Thursday, April 21st, 2022 | 2021 | Omar Khwaja, M.D., Ph.D. Former Chief Medical Officer and Head of Research and Development | 196,835 | 0 | 457,780 | 0 | 0 | 996,529 |
| Thursday, April 21st, 2022 | 2020 | Omar Khwaja, M.D., Ph.D. Former Chief Medical Officer and Head of Research and Development | 449,514 | 0 | 388,800 | 165,421 | 144,077 | 1,645,386 |
| Thursday, April 21st, 2022 | 2021 | Glenn Pierce, M.D., Ph.D. | 293,272 | 0 | 0 | 0 | 0 | 552,679 |
| Thursday, April 21st, 2022 | 2021 | Michael Higgins Former Interim President and Chief Executive Officer | 379,181 | 0 | 0 | 0 | 0 | 696,063 |
| Thursday, April 22nd, 2021 | 2020 | G. Andre Turenne President and Chief Executive Officer | 580,000 | 0 | 0 | 293,480 | 0 | 3,274,076 |
| Thursday, April 22nd, 2021 | 2019 | Robert W. Hesslein Senior Vice President and General Counsel | 307,500 | 0 | 0 | 134,500 | 0 | 3,240,961 |
| Thursday, April 22nd, 2021 | 2019 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 271,206 | 100,000 | 0 | 167,200 | 160,184 | 3,815,769 |
| Thursday, April 22nd, 2021 | 2020 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 449,514 | 0 | 0 | 165,421 | 144,077 | 1,645,386 |
| Thursday, April 22nd, 2021 | 2019 | G. Andre Turenne President and Chief Executive Officer | 540,800 | 0 | 0 | 256,880 | 0 | 2,844,090 |
| Thursday, April 22nd, 2021 | 2020 | Robert W. Hesslein Senior Vice President and General Counsel | 420,784 | 0 | 0 | 157,037 | 2,829 | 1,393,160 |
| Wednesday, April 22nd, 2020 | 2019 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 271,206 | 100,000 | 0 | 167,200 | 160,184 | 3,815,769 |
| Wednesday, April 22nd, 2020 | 2019 | Robert W. Hesslein Senior Vice President and General Counsel | 307,500 | 0 | 0 | 134,500 | 0 | 3,240,961 |
| Wednesday, April 22nd, 2020 | 2018 | G. Andre Turenne President and Chief Executive Officer | 240,000 | 0 | 0 | 143,325 | 0 | 8,209,845 |
| Wednesday, April 22nd, 2020 | 2019 | G. Andre Turenne President and Chief Executive Officer | 540,800 | 0 | 0 | 256,880 | 0 | 2,844,090 |
| Tuesday, April 23rd, 2019 | 2018 | Dinah Sah, Ph.D. Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 23rd, 2019 | 2017 | Matthew P. Ottmer Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 23rd, 2019 | 2017 | Dinah Sah, Ph.D. Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 23rd, 2019 | 2018 | G. Andre Turenne | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 23rd, 2019 | 2018 | Steven M. Paul, M.D. Former President and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 23rd, 2019 | 2017 | Steven M. Paul, M.D. Former President and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 23rd, 2019 | 2018 | Matthew P. Ottmer Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Friday, April 27th, 2018 | 2017 | Steven M. Paul, M.D. President and Chief Executive Officer | 506,900 | 0 | 0 | 239,510 | 48,303 | 2,655,385 |
| Friday, April 27th, 2018 | 2016 | Steven M. Paul, M.D. President and Chief Executive Officer | 485,100 | 0 | 0 | 242,550 | 18,304 | 3,435,514 |
| Friday, April 27th, 2018 | 2016 | Matthew P. Ottmer Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Friday, April 27th, 2018 | 2017 | Matthew P. Ottmer Chief Operating Officer | 124,359 | 0 | 0 | 132,300 | 0 | 2,829,384 |
| Friday, April 27th, 2018 | 2017 | Jane Pritchett Henderson Chief Financial Officer and Senior Vice President of Corporate Development | 370,000 | 0 | 0 | 119,318 | 80,417 | 2,246,682 |
| Friday, April 27th, 2018 | 2016 | Jane Pritchett Henderson Chief Financial Officer and Senior Vice President of Corporate Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 25th, 2017 | 2016 | Dinah Sah, Ph.D. Chief Scientific Officer | 330,800 | 0 | 0 | 99,240 | 0 | 1,142,485 |
| Tuesday, April 25th, 2017 | 2015 | Dinah Sah, Ph.D. Chief Scientific Officer | 315,000 | 0 | 0 | 78,750 | 0 | 819,923 |
| Tuesday, April 25th, 2017 | 2016 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 343,100 | 0 | 0 | 102,930 | 50,000 | 924,299 |
| Tuesday, April 25th, 2017 | 2015 | Steven M. Paul, M.D. President and Chief Executive Officer | 450,000 | 0 | 0 | 203,400 | 18,558 | 1,072,829 |
| Tuesday, April 25th, 2017 | 2015 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 336,400 | 0 | 0 | 76,020 | 50,000 | 551,279 |
| Tuesday, April 25th, 2017 | 2016 | Steven M. Paul, M.D. President and Chief Executive Officer | 485,100 | 0 | 0 | 242,550 | 18,304 | 3,435,514 |
| Friday, April 22nd, 2016 | 2015 | Bernard Ravina, M.D. Vice President, Clinical | 309,000 | 35,000 | 0 | 77,250 | 0 | 474,763 |
| Friday, April 22nd, 2016 | 2014 | Bernard Ravina, M.D. Vice President, Clinical | 231,731 | 66,060 | 0 | 0 | 0 | 387,791 |
| Friday, April 22nd, 2016 | 2014 | Steven M. Paul, M.D. President Chief | 150,000 | 0 | 0 | 0 | 5,870 | 1,032,820 |
| Friday, April 22nd, 2016 | 2015 | Steven M. Paul, M.D. President Chief | 450,000 | 0 | 0 | 203,400 | 18,558 | 1,072,829 |
| Friday, April 22nd, 2016 | 2015 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 336,400 | 0 | 0 | 76,020 | 50,000 | 551,279 |
| Friday, April 22nd, 2016 | 2014 | Robert Pietrusko, Pharm.D. Senior Vice President, | 174,792 | 1,161 | 0 | 0 | 50,000 | 350,953 |
